Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III
Cardiology · 2024
DOI: 10.1159/000536392 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cardiology, 2024. Verfasst von Meshal Alanezi und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Dyslipidemias, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Despite contemporary practice guidelines, a substantial number of post-acute coronary syndrome (ACS) patients fail to achieve guideline-recommended LDL-C thresholds. Our study aimed to investigate this guideline recommendations-to-practice care gap. Specifically, we aimed to identify opportunities where additional lipid-lowering therapies are indicated and explore reasons for the non-prescription of guideline-recommended therapies.
Methods
ACS patients with LDL-C ≥1.81 mmol/L (70 mg/dL) despite maximally tolerated statin ± ezetimibe therapy (including those intolerant of ≥2 statins) were enrolled 1–12 months post-event from 27 Canadian and US sites from September 2018 to October 2020 and followed up for three visits during the 12 months post-event. We determined the proportion of patients who did not achieve Canadian/US guideline-recommended LDL-C thresholds, the number of patients who would have been eligible for additional lipid-lowering therapies, and reasons behind lack of escalation in lipid-lowering therapies when indicated. Individual patient and aggregate practice feedback, including guideline-recommended intensification suggestions, were provided to each physician.
Results
Of the 248 patients enrolled in the pilot study (median age 64 [57, 73] years, 31.5% female and STEMI 27.4%), 75.4% were on high-intensity statins on the first visit. A total of 18.5% of those who attended all 3 visits had an LDL-C measured only at the first visit which was above the threshold. After 1 year of follow-up, 51.9% of patients achieved LDL-C thresholds at either visit 2 or 3. In the context of feedback reminding physicians about guideline-directed LDL-C-modifying therapy in their individual participating patients, we observed an increase in the use of ezetimibe and PCSK9 inhibitor therapy at 3–12 months. This was associated with a significant lowering of the mean LDL-C (from 2.93 mmol/L [baseline] to 2.09 mmol/L [3–6 months] to 1.87 mmol/L [6–12 months]) and a significantly greater proportion of patients (from 0% [baseline] to 38.6% [3–6 months] to 53.4% [6–12 months]) achieving guideline-recommended LDL-C thresholds. The most prevalent reasons behind the non-intensification of LDL-C-lowering therapy with ezetimibe and/or PCSK9i were LDL-C levels being close to target, the pre-existing use of other lipid-lowering therapies, patient refusal, and cost.
Conclusion
Although most patients post-ACS were on high-intensity statin therapy, almost 50% failed to achieve guideline-recommended LDL-C thresholds by 1-year follow-up. Furthermore, additional lipid-lowering therapies in this high-risk group were underprescribed, and this might be linked to several factors including potential gaps in physician knowledge, treatment inertia, patient refusal, and cost.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Toronto, Toronto, Ontario, Canada.
- St Michael's Hospital, Toronto, Ontario, Canada.
- Canadian Heart Research Centre, Toronto, Ontario, Canada.
- Moncton Hospital, Dalhousie University Faculty of Medicine, Moncton, New Brunswick, Canada.
- Cardio1 medical Clinic, Winnipeg, Manitoba, Canada.
- Beharry Medical Centre, Toronto, Ontario, Canada.
Zitieren
APA
Alanezi, M., Yan, A. T., Tan, M. K., Bourgeois, R., Malek-Marzban, P., Beharry, R., Alkurtass, S., Gyenes, G. T., Nadeau, P. L., Nwadiaro, N., Jedrzkiewicz, S., Gao, D., Chandna, H., Nelson, W. B., Goodman, S. G., & North American ACS Reflective III Pilot Investigators (2024). Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III. Cardiology. https://doi.org/10.1159/000536392
Vancouver
Alanezi M, Yan AT, Tan MK, Bourgeois R, Malek-Marzban P, Beharry R, et al. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III. Cardiology. 2024. doi:10.1159/000536392
BibTeX
@article{Alanezi2024,
author = {Alanezi, Meshal and Yan, Andrew T and Tan, Mary K and Bourgeois, Ronald and Malek-Marzban, Peiman and Beharry, Rani and Alkurtass, Suhaib and Gyenes, Gabor T and Nadeau, Pierre-Louis and Nwadiaro, Nduka and Jedrzkiewicz, Sean and Gao, Dongsheng and Chandna, Harish and Nelson, William B and Goodman, Shaun G and North American ACS Reflective III Pilot Investigators, North American ACS Reflective III Pilot Investigators},
title = {Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III},
journal = {Cardiology},
year = {2024},
doi = {10.1159/000536392}
}
EUVIMED